Form 4: Bioxytran CFO Exchanges Common Stock for Convertible Preferred Stock

Ola Soderquist, CFO of Bioxytran, Inc., executed a 5:1 exchange of common stock for convertible preferred stock on August 19, 2024.

Summary

• On August 19, 2024, Ola Soderquist, the CFO of Bioxytran, Inc. (BIXT), engaged in a transaction involving the company's stock.
• Soderquist exchanged 19,535,300 shares of common stock for convertible preferred stock at a ratio of 5:1.
• The CFO acquired 3,907,060 shares of preferred stock at a price of $0.05 per share as a result of the exchange.
• The convertible preferred stock has a conversion ratio of 1:5 into common stock.

Sentiment

Score: 5

Explanation: This Form 4 filing is a neutral event. It simply reports a transaction by an insider, and doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

This transaction is a routine disclosure of insider activity and doesn't necessarily indicate a broader trend in the biotechnology industry. However, it's important to monitor insider transactions as they can sometimes provide insights into management's perspective on the company's future prospects.

Stakeholder Impact

• The exchange of stock may have a minor impact on shareholders due to the change in the capital structure.
• Employees are unlikely to be directly affected by this transaction.
• Customers, suppliers, and creditors are unlikely to be directly affected by this transaction.

Key Dates

Keywords

Bioxytran, BIXT, CFO, Ola Soderquist, Form 4, Convertible Preferred Stock, Common Stock, Stock Exchange, Insider Trading